India Remdesivir market is anticipated to grow with an impressive CAGR in the forecast period, FY2023-FY2027. The market has shown a consistent growth in the last five years and it is expected to grow with the projected cumulative annular growth rate on the account of increasing prevalence of COVID-19 patients and the surge in the demand of drugs to overcome the viral infection. Moreover, the chronic diseases are rapidly increasing in the country, with changing lifestyle and the life choice of the population, the Remdesivir market in India is expected to grow in the upcoming five years. Also, India has a large number of geriatric populations, that is more prone to infectious diseases which in turn, is influencing the growth of India Remdesivir market growth, positively.
Remdesivir is an antiviral medication that is developed by the biopharmaceutical company Gilead Sciences. Administered via injection into a vein, the drug manufacturing process started in March 2020 with a research performed by Gilead Sciences Inc. The research was performed on 53 prospective COVID-19 patients out of which only 36 patients showed signs of progress that accounted for about 68% of the total number of patients. World Health Organization has guided the start of clinical trials for the drug along with three other drugs found to be effective in COVID-19 therapy. Remdesivir drug has reached phase 3 of clinical trials and the world hopes it will emerge as a promising treatment for COVID-19. Following these positive trials, the food and drug administration issued permission for the medication to treat Covid-19 for emergency use authorization (EUA). That means the medication has not undergone the same examination as therapies approved by the FDA, but it will allow doctors to prescribe Remdesivir to patients hospitalized with the disease. All supply of drugs will go to the government for allocation across the nation.
India Remdesivir market segmentations is based on
Some of the top players in the India Remdesivir Market are, Cipla Ltd., Hetero Labs Pvt. Ltd., Jubilant Life Sciences Ltd., Viatris Pharmaceuticals Ltd. (Mylan Laboratories India Pvt. Ltd.), Dr. Reddy’s Laboratories Ltd., Sun Pharmaceuticals Industries Ltd., Zydus Cadila Healthcare Ltd., Pfizer Ltd., Gilead Sciences India Private Limited, Eva Pharma Pvt. Ltd., among others. The companies are involving themselves into research and development for more advanced form of the drug. Remdesivir is the therapeutic drug against the coronavirus, COVID-19 and are in demand owing to the need of the healthcare industry in the country. Although the export of the drug is increasing rapidly to satisfy the consumer demand. New players entering the market may form partnerships with other players or the end users of the industry for a consistent inflow of the product.
Years considered for this report
Historical YearsFY2017 – FY2020
Base YearFY2021
Estimated YearFY2022
Forecast PeriodFY2023 – FY2027
Objective of the Study
- To analyze the historical growth of the market size of India Remdesivir market from FY2017 to FY2020.
- To estimate and forecast the market size of India Remdesivir market from FY2021 to FY2027 and growth rate until FY2027.
- To classify and forecast India Remdesivir market based on application, route of administration, dosage form, patient age, distribution channel, competitional landscape, and regional distribution.
- To identify dominant region or segment in the India Remdesivir market.
- To identify drivers and challenges for India Remdesivir market.
- To examine competitive developments such as expansions, new product launches, mergers & acquisitions, etc., in India Remdesivir market.
- To identify and analyze the profile of leading players operating in India Remdesivir market.
- To identify key sustainable strategies adopted by market players in India Remdesivir market.
Click here to download the sample
TechSci Research performed both primary as well as exhaustive secondary research for this study. Initially, TechSci Research sourced a list of manufacturers, suppliers, and service providers across the country. Subsequently, TechSci Research conducted primary research surveys with the identified companies. While interviewing, the respondents were also enquired about their competitors. Through this technique, TechSci Research could include the manufactures which could not be identified due to the limitations of secondary research. TechSci Research analyzed the manufactures, distribution channels and presence of all major players across the country.
TechSci Research calculated the market size of India
Key Target Audience
- Remdesivir manufacturers, end users, and other stakeholders
- Distributers and suppliers of Remdesivir and other stakeholders
- Organizations, forums and alliances related to coronavirus drugs
- Market research and consulting firms
The study is useful in providing answers to several critical questions that are important for the industry stakeholders such as manufacturers, suppliers, end users, etc., besides allowing them in strategizing investments and capitalizing on market opportunities.
